Activated Foam

Abstract

The present invention relates to an activated foam made of a natural or synthetic rubber or a synthetic resin, characterized in that the foam contains a zirconium compound and/or a germanium compound, and has a closed-cell structure, wherein the foam is used so as to directly or indirectly contact with a human body when a pharmaceutical agent is administered. The activated foam can be directly or indirectly contacted with a human body to facilitate blood circulation and promote the improvement of physical condition and the cure of diseases. It also has no adverse effect.

1 . An activated foam made of a natural or synthetic rubber or a synthetic resin, wherein said foam contains a zirconium compound and/or a germanium compound, and has a closed-cell structure, and further wherein said foam is used so as to directly or indirectly contact with a human body when a pharmaceutical agent is administered.  
   
   
       2 . An activated foam made of a natural or synthetic rubber or a synthetic resin, wherein said foam contains a zirconium compound and/or a germanium compound and carbon, and has a closed-cell structure, and further wherein said foam is used so as to directly or indirectly contact with a human body when a pharmaceutical agent is administered.  
   
   
       3 . The activated foam according to  claim 1 , wherein said pharmaceutical agent is an anti-cancer agent.  
   
   
       4 . The activated foam according to  claim 3 , wherein said pharmaceutical agent is a human-derived anticarcinogenic substance.  
   
   
       5 . The activated foam according to  claim 4 , wherein said human-derived anticarcinogenic substance is an inhibitor of histone deacetylase (HDACI).  
   
   
       6 . The activated foam according to  claim 1 , wherein said cell is formed at 20 to 30 cells/mm 2 .  
   
   
       7 . The activated foam according to  claim 2 , wherein said pharmaceutical agent is an anti-cancer agent.  
   
   
       8 . The activated foam according to  claim 7 , wherein said pharmaceutical agent is a human-derived anticarcinogenic substance.  
   
   
       9 . The activated foam according to  claim 8 , wherein said human-derived anticarcinogenic substance is an inhibitor of histone deacetylase (HDACI).  
   
   
       10 . The activated foam according to  claim 2 , wherein said cell is formed at 20 to 30 cells/mm 2 .  
   
   
       11 . The activated foam according to  claim 3 , wherein said cell is formed at 20 to 30 cells/mm 2 .  
   
   
       12 . The activated foam according to  claim 4 , wherein said cell is formed at 20 to 30 cells/mm 2 .  
   
   
       13 . The activated foam according to  claim 5 , wherein said cell is formed at 20 to 30 cells/mm 2 .  
   
   
       14 . The activated foam according to  claim 6 , wherein said cell is formed at 20 to 30 cells/mm 2 .  
   
   
       15 . The activated foam according to  claim 7 , wherein said cell is formed at 20 to 30 cells/mm 2 .  
   
   
       16 . The activated foam according to  claim 8 , wherein said cell is formed at 20 to 30 cells/mm 2 .  
   
   
       17 . The activated foam according to  claim 9 , wherein said cell is formed at 20 to 30 cells/mm 2 .